Background. Treatment options for vancomycin-resistant enterococci (VRE) bloodstream infection (BSI) are limited. Daptomycin, although not currently approved for this indication, is frequently used for the treatment of VRE-BSI. Its optimal dose still needs to be determined.
Vancomycin-resistant enterococci (VRE) were first described in 1986 [1, 2] and have emerged as important pathogens for nosocomial infections [3] . Treatment options for VRE are limited [4] . Daptomycin is an attractive option as it exhibits concentration-dependent bacterial killing [5] and has been shown to exert rapid bactericidal activity against enterococci [6] . It is increasingly being used for the treatment of VRE bacteremia [7] even though it is currently not approved by the US Food and Drug Administration for this indication.
A systematic review and metaanalysis published several years ago showed that daptomycin was less effective than linezolid for the treatment of VRE bloodstream infection (BSI) [7, 8] . An inadequate dose of daptomycin might be one of the reasons for this [9, 10] . A smaller retrospective study also showed that a daptomycin dose of >6 mg/kg was associated with better VRE infection outcome [11] . A 10-mg/kg daptomycin dose exhibited a more rapid bactericidal action against VRE than a 6-mg/kg dose [12] . A more recent study showed that higher doses of daptomycin were more effective than linezolid in the treatment of VRE bacteremia [13] . The 6-mg/ kg dose was based on the treatment of Staphylococcus aureus bacteremia. However, gram-positive bacteria have different pharmacodynamics (PD) parameter targets [14] , and the optimal daptomycin dose for the treatment of VRE bacteremia still needs to be determined. In addition, another recent study showed that VRE isolates with a higher daptomycin minimum inhibitory concentration (MIC), although still susceptible, were associated with increased microbiological failure [15] .
Our aim in this study was to determine whether higher doses of daptomycin were more effective than customary doses in decreasing the mortality rate in VRE-BSI patients. The secondary aim was to determine whether a daptomycin MIC within the susceptible range could influence clinical outcomes.
METHODS

Hospital Setting and Patients
This study was conducted at the National Taiwan University (NTUH), a 2200-bed medical center located in the Taipei City, and at the NTUH-Yun-Lin branch, a 600-bed metropolitan hospital in Yun-Lin county. The research ethics committee of the NTUH approved the study. The committee waived the requirement for informed consent.
Patients with VRE bacteremia were prospectively enrolled from January 2010 through July 2015. Patients were identified through daily computer-generated microbiology reports, and VRE bacteremia was defined as the growth of VRE in ≥ 1 blood cultures. If a patient had multiple episodes of VRE bacteremia during the study period, only the first episode was included. The clinically evaluable cohort consisted of patients who met all the following criteria: who received a daptomycin dose of ≥6 mg/kg; whose VRE isolates were susceptible to daptomycin (≤4 mg/L); and who were initially treated with daptomcyin for the VRE bacteremia and subsequently completed the entire treatment course or until death. Patients aged <18 years or those not hospitalized were excluded. Patients who survived more than 7 days but received no follow-up blood cultures, or received daptomycin for less than 72 hours, or received daptomycin after the VRE bacteremia had cleared were excluded from the microbiologically evaluable cohort. The daptomycin dose (≥6 mg/kg) was selected by the attending physicians. Currently in Taiwan, there are no illness severity-based local guidelines to select daptomycin dose for the treatment of VRE bacteremia.
Microbiological Studies and Antimicrobial Susceptibility Testing
Blood cultures were processed by the clinical microbiology laboratory. Enterococcus spp. were identified using the VITEK 2 identification system. Vancomycin resistance was defined as an enterococcus isolate with a vancomycin MIC of ≥32 mg/L. VRE isolates collected at the 2 hospitals were stored at −80ºC until use. MIC testing of all available isolates was performed at the NTUH. The daptomycin MICs of enterococci were determined using the broth microdilution (BMD) method and were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) [16] . Cation-adjusted Mueller-Hinton broth (Becton Dickinson, Le Pont-de-Claix, France), with 50 μg/mL of supplemented calcium, was used. All MIC tests were performed by the same well-trained technician using the same batch of medium. Enterococcus faecalis (ATCC 29212) and Staphylococcus aureus (ATCC 29213) were used as the quality control strains. Etest (bioMérieux, Marcy-l′Etoile, France) was performed on MuellerHinton agar (MHA) (Becton Dickinson, Le Pont-de-Claix, France) in accordance with the manufacturer's instructions.
Clinical Data Collection and Definitions
Demographic data, underlying diseases, and sites of infection were obtained from electronic medical records. We classified the bacteremia as primary if an infectious focus could not be identified. Cather-related BSI and central line-associated BSI (CLABSI) were defined according to previous definitions [17] . The severity of infection at bacteremia onset was assessed using the Pitt bacteremia score [18] .
Patients were followed daily through a review of their electronic records. The daptomycin dose was calculated according to the actual body weight [19] . Use of immunosuppressive agents was defined as the administration of antineoplastic drugs, cyclophosphamide, or other immunosuppressive agents within 6 weeks of bacteremia onset or the administration of prednisolone at a dosage ≥20 mg/day for ≥2 weeks or 30 mg/ day for ≥1 week within 6 weeks of bacteremia onset [20] . Thrombocytopenia was defined as a platelet count of <50 000/ μL [13] . At both hospitals, we recommended that a creatine kinase (CK) level be determined at least once per week during daptomycin treatment [10] or if the patients were symptomatic. An elevated CK level was defined as a level higher than the normal upper limit [11] . A high CK elevation was defined as a CK level more than 10-fold greater than the normal upper limit. The Naranjo algorithm was used to assess adverse drug reactions [21] . Creatinine clearance was estimated using the Cockcroft-Gault equation [22, 23] .
All causes of in-hospital mortality were recorded. The primary study outcome was the 14-day mortality. The secondary study outcomes included microbiological failure, clinical failure, and a CK level elevation. Microbiological failure was defined as VRE isolated in a follow-up blood culture ≥4 days after the onset of VRE bacteremia [15] or death within 7 days of bacteremia onset without the clearance of VRE. Clinical failure was defined as 14-day mortality or microbiological failure.
Statistical Analyses
The median and the interquartile range (IQR) were calculated for continuous variables, and percentages were calculated for categorical variables. Continuous variables were compared between 2 or 3 groups using a Mann-Whitney U test or a Kruskal-Wallis 1-way analysis of variance test, respectively. Categorical variables were compared using a χ 2 test or a 2-tailed Fisher exact test, when appropriate. Multivariable logistic regression was performed to analyze the outcomes. Variables with a P value of ≤0.2 in a univariable regression analysis were included in the multivariable analysis. Multivariable models were developed using a backward, stepwise, minimizing Akaike's information criterion (AIC) [24] . Following the stepwise AIC selection, only variables with a P value of ≤.05 were considered significant and were retained in the final model. The interaction between the influence of daptomycin dose and MIC on patient outcome was examined using stratification and marginal effects analysis.
To transform the variable "daptomycin dose" into a categorical variable that could then be used to clearly differentiate the patient outcome (14-day mortality) in different strata, we divided the daptomycin dose into quartiles to set daptomycin dose cutoff values. Further, to ensure clinical relevance of the daptomycin dose quartile cutoffs, we rounded them off to the nearest integer values. The different dose cutoffs were examined in a multivariable model, and the goodness-of-fit of the multivariable models was examined using a Hosmer-Lemeshow goodness-of-fit test. Stata software (v. 14; StataCorp, College Station, Texas) was used to perform all statistical analyses. Twotailed P values of ≤.05 were considered statistically significant.
RESULTS
A total of 309 VRE bacteremia episodes were identified during the 2010-2015 study period ( Figure 1 ). Of these, 112 met the inclusion criteria of being treated with daptomycin and having evaluable clinical outcomes. All patients were infected with Enterococcus faecium. Seventy-three patients had primary bacteremia, and 49 among them were classified as CLABSI. The median (IQR) age of the study cohort was 64.8 (53.0-78.9) years (Table 1) . Seventy-eight (69.6%) isolates were susceptible to daptomycin at a MIC of 4 mg/L and 34 (30.4%) at ≤2 mg/L. The 14-day mortality was 40/112 (35.7%). The evaluable microbiological failure rate was 31/56 (55.4%), and the clinical failure rate was 56/112 (50.0%).
The baseline characteristics of the survivors and nonsurvivors are summarized in Table 1 . The nonsurvivors exhibited lower platelet counts (5.9 × 10 4 /μL vs 9.4 × 10 4 /μL; P = .007).
They were more likely to have been treated with corticosteroids (32.5% vs 6.9%; P < .001) and exhibited greater disease severity based on the Pitt bacteremia score (4 vs 2; P = .008). Further, the survivors had received higher daptomycin doses (7.9 mg/ kg vs 7.3 mg/kg; P = .02). There was no significant difference in concomitant β-lactam use between the survivors and the nonsurvivors (P = .29).
We performed a stepwise, multivariable logistic regression analysis to adjust for the differences in the baseline characteristics of the survivors and nonsurvivors, including body weight. Supplementary Figure 1 ). This decrease in mortality odds was independent of steroid use, the Pitt bacteremia score, and platelet counts.
Association Between Daptomycin Dose, MIC, and Mortality
To determine the association between daptomycin dose and MIC, we included this interaction term in the multivariable logistic regression for marginal effects analysis. There was no significant difference in patient mortality with a daptomycin MIC = 4 mg/L compared to a MIC ≤2 mg/L (aOR, 0.55; 95% CI, 0.001-268.71; P = .85). The interaction term between daptomycin dose and a daptomycin MIC = 4 mg/L exhibited an aOR of 1.05 (95% CI, 0.48-2.28; P = .91). Higher daptomycin doses were consistently associated with lower mortality regardless of a daptomycin MIC = 4 mg/L or MIC ≤2 mg/L (aOR, 0.59; 95% CI, 0.41-0.86; P = .006 and aOR, 0.61; 95% CI, 0.42-0.88; P = .008, respectively) (Supplementary Figure 2) . We assessed the impact of daptomycin MIC and daptomycin dose on mortality by dividing the daptomycin dose into quartiles (Figure 2) . The trend for dose-dependent response remained similar in the group with daptomycin MIC = 4 mg/L, though the mortality rate was relatively similar between the second and third daptomycin dose quartile groups (8/23, 34.8% vs 7/21, 33.3%). Figure 2 . Mortality at different daptomycin doses and minimum inhibitory concentrations. Abbreviations: MIC, minimum inhibitory concentration; Q1, first dose quartile; Q2, second dose quartile; Q3, third dose quartile; Q4, fourth dose quartile.
Selection of the Cutoff Dose for Daptomycin
The fourth daptomycin dose quartile was associated with the lowest mortality (5/27, 18.5%), followed by the third quartile (9/28, 32.1%), the second quartile (12/29, 41.4%), and the first quartile (14/28, 50%). The association between daptomycin dose quartile and patient mortality was further confirmed by a multivariable logistic regression analysis (Supplementary  Table 1 , model 1). We rounded the daptomycin quartile cutoffs to the nearest integer values. Following the rounding off, higher daptomycin doses of ≥9 mg/kg remained significantly associated with lower mortality compared to lower daptomycin doses (Supplementary Table 1, model 2) . The daptomycin doses of 7-8 mg/kg and 8-9 mg/kg had similar effect size for mortality prediction. Next, we set the daptomycin dose cutoffs to <7 mg/ kg, 7-9 mg/kg, and ≥9 mg/kg. With these cutoffs, the daptomycin dose of ≥9 mg/kg was associated with the best patient outcome (aOR, 0.09; 95% CI, 0.02-0.44; P = .003) compared to a daptomycin dose of <7 mg/kg ( Table 2 ). The Pitt bacteremia score (P = .79), Charlson score (P = .95), and the time to daptomycin initiation (P = .96) did not differ between the above-mentioned daptomycin dose groups ( Table 3 ). The major difference among these dose groups was the patients' body weight (P = .001).
Sensitivity Analysis
We selected 97 patients who had received daptomycin for at least 72 hours for the sensitivity analysis. Patients who had received a daptomycin dose of ≥9 mg/kg had a lower mortality than those who received a dose of 6-9 mg/kg (3/22, 13.6% vs 23/75, 30.7%; P = .11). In a multivariable logistic regression analysis performed on the sensitivity analysis cohort, the mortality odds of patients with VRE-BSI decreased by 38% for each milligram per kilogram increase in the daptomycin dose (aOR, 0.62; 95% CI, 0.41-0.93; P = .02).
We also excluded 27 patients whose bacteremia resolved before daptomycin administration for the sensitivity test. However, despite this exclusion, we could still note that a daptomycin dose of ≥9 mg/kg was associated with significantly lower mortality (aOR, 0.06; 95% CI, 0.01-0.40; P = .004).
Microbiological Outcome
A microbiological failure occurred in 31 of the 56 evaluable patients (55.4%). There was no significant difference in microbiological failure frequency for patients with a VRE daptomycin MIC = 4 mg/L compared to those with a MIC of ≤2 mg/L (20/37, 54.1% vs 11/19, 57.9%; P = .78). The median (IQR) daptomycin dose in the microbiological failure group was 7.8 mg/ kg (6.5-8.7 mg/kg) and that in the nonfailure group was 7.6 mg/ kg (6.9-8.4 mg/kg; P = .93). Multivariable analysis revealed that primary bacteremia (aOR, 3.56; 95% CI, 1.05-12.08; P = .04) and a per 10 000/μL increment in platelet count (aOR, 0.91; 95% CI, 0.85-0.98; P = .02) were the only 2 significant independent predictors of microbiological failure.
Elevation of Creatine Kinase
Seven cases showed an elevated CK level and were classified as probable adverse drug reaction cases (Table 3) . However, no significant association was noted between the daptomycin dose and the elevated CK level (P = .99). Moreover, only 1 patient in the <7-mg/kg daptomycin dose group exhibited a high CK elevation.
DISCUSSION
We found an association between the administered daptomycin dose and survival in patients with a VRE-BSI. We further observed that this association was independent of the daptomycin MIC exhibited by the susceptible isolates. Higher doses of daptomycin were associated with lower mortality in a dosedependent manner. A daptomycin dose of ≥9 mg/kg was associated with better patient survival than a dose of 7-9 mg/kg, followed by that of 6-7 mg/kg.
Platelets play an important role in the immune system [25] , and a decreased platelet count is a sign of sepsis-associated organ dysfunction [26] . Thrombocytopenia has been identified as a risk factor for mortality among enterococcal bacteremia patients [27] . In our study, a higher daptomycin dose remained significantly associated with lower mortality even when adjusted for steroid use, disease severity (Pitt bacteremia score), and platelet counts. These findings suggest that daptomycin doses greater than the customary dose of 6 mg/kg should be considered for the treatment of VRE bacteremia.
The area under the curve (AUC)/MIC or the peak/MIC are the PD parameters that best correlate with the in vivo efficacy of daptomycin [14] . Increased daptomycin doses are also associated with increased AUC [28, 29] . Theoretically, both the daptomycin dose and the daptomycin MIC should affect the PD parameter of AUC/MIC. In this study, however, we did not find an independent association between the daptomycin MIC and patient mortality. The BMD method for MIC testing may not have been sufficiently robust to detect higher MICs for E. faecium [15, 30] . Shukla et al reported that isolates with a higher daptomycin MIC, as determined using an Etest, although still susceptible, were associated with increased microbiological failure [15] . However, in that study, the Etest-determined MIC was not significantly correlated with that by BMD [15] . Controlling the calcium content in agar-based media is difficult. In addition to the variability in MHA calcium concentrations, the high molecular weight of daptomycin results in its slow diffusion through agar-based media [31] . Etest is not recommended by the CLSI for VRE daptomycin MIC testing. Therefore, the main results of daptomycin MIC reported here were determined using BMD rather than the Etest. However, we obtained similar results in the outcome analysis with Etest-determined daptomycin MIC values (Supplementary Materials and Supplementary  Table 2 ). The VRE isolates in our study tended to have higher daptomycin MICs [15] . Therefore, the daptomycin dose may play a more important role in predicting the outcome of VRE bacteremia than the MIC. A previous report noted an association between the frequency of elevated CK levels and the use of high-dose daptomycin (>8 mg/kg) [32] . However, other investigators did not find such an association [33] and have, therefore, considered higher daptomycin doses to be generally safe [33] [34] [35] . To ensure maximum drug safety, we suggest that the patients' CK levels be monitored closely until the optimal safe dose is finally determined.
The strengths of this study include the enrollment of a large study population at 2 teaching hospitals using the same patient selection protocol. The wide range of daptomycin doses used in this patient population allowed us to determine dose-related efficacy and safety. Further, the assessment of microbiological endpoints and their relation to the MICs of the VRE isolates provided important information. Additionally, the primary endpoint of 14-day mortality allowed us to avoid the possible subjective confounders of longer survival times for patients with multiple comorbidities [36, 37] .
This study has several limitations. We were compelled to conduct an observational study due to the participating physicians' concerns regarding drug toxicity and the controversy regarding the optimal daptomycin dose to be used for VRE-BSI. The multivariable regression analysis may not have included other unknown confounders. In comparison to other studies, we observed a relatively higher frequency of primary bacteremia in our study population [13, 15] . This may be because the infection foci were not only inferred by the primary care physician but also needed to be confirmed by cultures. In addition, due to the observational study design, only 36 of the 73 primary bacteremia patients had received an echocardiogram. Furthermore, as our study population comprised only a very small number of solid organ transplant, leukemia, and bone marrow transplantation patients, the effect of daptomycin dose in such patients would need further validation.
In conclusion, we observed that the clinical effectiveness of daptomycin for the treatment VRE bacteremia was dose dependent. High-dose daptomycin, particularly a dose of ≥9 mg/kg, was associated with better patient survival than low-dose daptomycin. High-dose daptomycin appeared to be safe and should be considered for the treatment of bacteremia caused by daptomycin-susceptible VRE. Further studies, including controlled clinical trials, are needed to ensure the safety and efficacy of a daptomycin dose of ≥9 mg/kg compared to the customary dose (6 mg/kg) used for the treatment of VRE bacteremia.
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